The estimated Net Worth of Mark F Dalton is at least $322 Tisíc dollars as of 14 May 2008. Mark Dalton owns over 7,500 units of Progenics Pharmaceuticals stock worth over $321,850 and over the last 22 years Mark sold PGNX stock worth over $0.
Mark has made over 1 trades of the Progenics Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Mark exercised 7,500 units of PGNX stock worth $40,200 on 14 May 2008.
The largest trade Mark's ever made was exercising 7,500 units of Progenics Pharmaceuticals stock on 14 May 2008 worth over $40,200. On average, Mark trades about 750 units every 0 days since 2003. As of 14 May 2008 Mark still owns at least 78,500 units of Progenics Pharmaceuticals stock.
You can see the complete history of Mark Dalton stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 1275 KING STREET, , GREENWICH, CT, 06831.
Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch a Bradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.
Progenics Pharmaceuticals executives and other stock owners filed with the SEC include: